ada standards of care 2025 obesity pharmacotherapy glp-1 ACC Scientific Statement on the Management in Adults With Heart Failure: A Report of the American College of Cardiology Recent progress in the pharmacotherapy

Factors Affecting Glutathiones Effectiveness Frequency and amount Results may be changed by the right dose regularity and amount

What is the bioavailability difference between injectable and oral peptides

Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin and Visceral Adiposity Research studies have observed a reduction in visceral adiposity in test models exposed to Tesamorelin

Zepbound Lawsuit 2026 Update July 1, 2026: Over 80 Lawsuits About Zepbound, Similar GLP-1 Drugs Join the MDL The consolidated multidistrict litigation about Zepbound and other GLP-1 products has grown to include 3,848 lawsuits as of July 1, 2026

Dasiglucagon effectively mitigates postbariatric postprandial hypoglycemia: a randomized, double-blind, placebo-controlled, crossover trial